Generic Name : ERENUMAB ABSTRACT – Aimovig is a drug used for the prevention of migraines in adults. It...
Erenumab (trade name Aimovig) is a medication which targets the calcitonin gene-related peptide receptor (CGRPR) for the prevention of migraine. It was the first of the group of CGRPR antagonists to be FDA approved in 2018.
It is a form of monoclonal antibody therapy in which specially cultured antibodies are used to stimulate the patient’s immune system into attacking the receptors for the protein CGRP, thought to play a major role in starting migraines. Erenumab is approved for prevention of migraine in adults.
It is administered by subcutaneous injection of 70 or 140 mg once a month.
Common side effects are constipation, pruritus, muscle spasms, as well as mild and mostly transient reactions at the injection site.
Erenumab was shown not to interact with ethinyl estradiol, norgestimate or the migraine drug sumatriptan. It is expected to generally have a low potential for interactions because it is not metabolized by cytochrome P450 enzymes.
Erenumab is a fully humanized monoclonal antibody blocking the calcitonin gene-related peptide receptor (CGRPR).This medication was developed by Amgen Inc in conjunction with Novartis